**Tables:**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Parameters | Type 2 diabetic patients with overweight | | | | | | | | | p |
| Total | | | Group 1 | | | Group 2 | | |
| Baseline | Metformin  (12 W) | Metformin +  SGLT2 inhibitors  (24 W) | Baseline | Metformin  (12 W) | Metformin + Dapagliflozin (24 W) | Baseline | Metformin  (12 W) | Metformin + Empagliflozin (24 W) |
| RBP4 (μg/mL) | 95.10±12.04 | 95.27±11.87 | 89.40±11.36a | 93.43±12.02 | 97.00±12.30 | 90.94±11.64b | 93.43±12.02 | 93.29±11.49 | 87.64±11.20b |  |
| Change | 0.15 (-0.50, 0.79), -5.85 (-6.87, -4.84) | | | 0.44 (-0.51, -1.39), -6.06 (-7.57, -4.56) | | | -0.14 (-1.13, -0.85), -5.64 (-7.18, -4.10) | | | 0.439 |
| FABP4 (ng/mL) | 45.78±4.24 | 45.81±4.24 | 42.63±4.11a | 46.41±4.32 | 46.50±4.29 | 43.06±4.41b | 45.05±4.17 | 45.01±4.20 | 42.15±3.84b |  |
| Change | 0.02 (-0.23, 0.27), -3.15 (-3.65, -2.65) | | | 0.08 (-0.20, 0.36), -3.44 (-4.10, -2.78) | | | -0.04 (-0.52, 0.44), -2.86 (-3.70, -2.02) | | | 0.420 |
| Visfatin (ng/mL) | 8.49±0.99 | 8.63±0.99a | 7.19±0.97a | 8.58±0.95 | 8.74±0.93b | 7.36±0.87b | 8.40±1.06 | 8.50±1.06b | 6.99±1.08b |  |
| Change | 0.13 (-0.06, 0.20), -1.44 (-1.59, -1.29) | | | 0.17 (0.06, 0.28), -1.38 (-1.64, -1.12) | | | -0.10 (-0.01, -0.20), -1.51 (-1.67, -1.34) | | | 0.468 |
| Adiponectin (μg/mL) | 10.36±1.79 | 10.33±1.79 | 14.61±1.80a | 10.49±1.98 | 10.43±1.97 | 14.68±1.20b | 10.21±1.60 | 10.23±1.63 | 14.53±1.61b |  |
| Change | -0.02 (-0.10, 0.05), 4.28 (3.90, 4.66) | | | -0.06 (-0.17, -0.04), 4.26 (3.67, -4.84) | | | 0.01 (-0.11, -0.14), 4.30 (3.74, 4.86) | | | 0.752 |
| Data are means ± SD, or 95% CI. p < 0.05 was considered significant.  SGLT2: Sodium glucose cotransporter 2, RBP4: Retinol binding protein 4, FABP4: Fatty acid binding protein 4.  a p < 0.05 (comparison between before treatment and after treatment in all subjects)  b p < 0.05 (comparison between before treatment and after treatment in each group) | | | | | | | | | | |

Table 4: Change from baseline to treatment with metformin, before and after add-on therapy of SGLT2 inhibitors on adipokines in overweight type 2 diabetes.